Source: MarketScreener

Nuvo Pharmaceuticals: Nuvo Pharmaceuticals : reg; Announces First Quarter 2020 Results

(marketscreener.com) ٠ Q1 2020 Adjusted Total Revenue - $18.9 million ٠٠ Q1 2020 Adjusted EBITDA - $8.0 million ٠٠ Blexten Canadian Prescriptions Increased 54% Year-Over-Year ٠٠ Cambia Canadian Prescriptions Increased 30% Year-Over-Year ٠ Virtual Annual & Special Meeting of Shareholders -...https://www.marketscreener.com/NUVO-PHARMACEUTICALS-INC-46874517/news/Nuvo-Pharmaceuticals-reg-Announces-First-Quarter-2020-Results-30579588/?utm_medium=RSS&utm_content=20200511

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Jesse Ledger's photo - President & CEO of Nuvo Pharmaceuticals

President & CEO

Jesse Ledger

CEO Approval Rating

91/100

Nuvo is a healthcare company that manufactures and commercializes pharmaceutical products for the topical pain relief. Read more